![]() |
The new stock research experience is built to take
advantage of the latest browser technology.
RELATED RESOURCES |
The current research page will be phased out by summer.
Click Use New Research and get the same data you use today,
plus new tools and insights.
Snapshot:RNLXRENALYTIX PLC2.60
|
|
Company ProfileLog in for more informationRenalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data… ![]() Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York. ![]() Sector (GICS®)Health CareIndustry (GICS®)Health Care TechnologyEnvironmental, Social & Governance Summary (ESG)![]() ESG ratings enable you to leverage independent ESG research to evaluate how companies are managing ESG risks and addressing ESG opportunities. Learn more About Environmental, Social & Governance Summary (ESG)MSCI ESG RatingsEnvironmental, Social, and Governance (ESG) Flags: MSCI Ratings publishes Environmental, Social and Governance (ESG) ratings on over 6,000 companies worldwide. These ratings provide an independent assessment of the sustainable investment value of public companies. The ESG Ratings model is based on a carefully crafted and applied list of KeyMetrics® that result in an overall ESG concern level as expressed by Red (High Concern), Yellow (Average Concern), and Green (Low Concern) flags. Unlike traditional ESG risk models, MSCI's rating methodology is designed to identify risks most likely to affect equity valuations. Specifically, these ratings reflect actual corporate behaviors rather than policies or affirmations of intent to adhere to best ESG practices. Further, unlike other models with evenly weighted metrics, we assign context-sensitive relative weightings to our key metrics, based on market, regional, ownership or sector differences. Individual company scores are then assigned as a percentile rank, ranging from 1 (worst ranked) to 100 (best) on the basis of these KeyMetrics® and then converted to the Red, Yellow or Green flag designation. Company Reports: In addition to a company's overall risk rating, ESG reports also include an industry rating based on a comparison between the company's risk levels in each ESG component area relative to its industry peers. Further, the ESG analysis serves as a summary of behavioral events that contributed to the company's overall risk level. Full Time Employees: 54
Executives
renalytix.com
1460 Broadway 1-646 397 3970 |
Analyst OpinionsThe Equity Summary Score is an accuracy-weighted sentiment derived from the ratings of independent research providers on Fidelity.com. It uses the past relative accuracy of the providers in determining the emphasis placed on any individual opinion. Learn More.... Log in to view the Equity Summary Score for RNLX
Log in
to view all Analyst Opinions for RNLX
Research Reports
Company Research Highlights® Report (PDF)
This generated report* compiles independent, third-party information highlighting key fundamental and technical data, analyst opinions, stock price movement, earnings data, and industry comparisons. Available only to Fidelity customers.
Compustat ® Company Report
This generated report* has historical data on financials with interactive charts, technical indicators, and five-year peer comparison trend charts.
*Generated reports are built dynamically when you select them. Reports may not be available for some symbols. Select the link to check availability for this symbol.
RNLX Industry Comparison: |